ST
CATX icon

Smithfield Trust’s Perspective Therapeutics CATX Stock Holding History

Smithfield Trust’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-200
Closed -$1K – 827
2013
Q4 		$1K Hold
200
– – ﹤0.01% 813
2013
Q3 		$1K Hold
200
– – ﹤0.01% 723
2013
Q2 		$1K Buy
+200
New +$1.08K ﹤0.01% 724

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
SFSIG
San Francisco Sentry Investment Group San Francisco, California $192M AUM 276.26% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
IFS
Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return

Smithfield Trust's CATX Position: Q1 2014 in Review

Smithfield Trust sold out of Perspective Therapeutics (CATX) in Q1 2014, closing a stake of 200 shares — an estimated $1K sold.

Smithfield Trust first reported a position in CATX in Q2 2013 and held it in 3 quarters. The position peaked at $1K in Q4 2013. 25 funds tracked by Wall St. Rank hold CATX as of Q1 2014.

  • Smithfield Trust reported no remaining Perspective Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Smithfield Trust sold 200 Perspective Therapeutics shares in Q1 2014, an estimated $1K.
  • Smithfield Trust first reported a position in Perspective Therapeutics in Q2 2013 and held it in 3 quarters.
  • Smithfield Trust's Perspective Therapeutics position peaked at $1K in Q4 2013.
  • 25 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2014.

Based on Smithfield Trust's 13F filing for Q1 2014, filed 6 May 2014.